DelveInsight’s “Nasal Polyposis Market Insights, Epidemiology, and Market Forecast 2034” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Nasal Polyposis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Nasal Polyposis market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Key highlights from the Nasal Polyposis Market Report:
In 2023, the market for nasal polyposis across the 7MM was approximately USD 1,910 million, and it is projected to grow significantly by 2034, reflecting a strong Compound Annual Growth Rate (CAGR) throughout the study period from 2020 to 2034.
The United States represents the largest segment of nasal polyps market, accounting for about 72% of the total nasal polyps market size in 7MM.
Emerging therapies, such as Fasenra (benralizumab) and Tezepelumab, are expected to drive substantial growth in the nasal polyposis market.
Among European countries, Germany reported the highest market size, reaching USD 154 million in 2023.
The anticipated introduction of new therapies, combined with an increase in the diagnosed prevalence of nasal polyposis, is expected to further boost the market size in the coming years.
Several factors are contributing to the rising incidence of diagnosed nasal polyposis cases across the 7MM (the seven major markets), including heightened awareness and improved diagnostic practices. Environmental influences, such as air pollution, allergens, and shifting climate patterns, may also play a role by triggering inflammation and nasal congestion, which are associated with the development of nasal polyps.
In 2023, the United States reported the highest number of diagnosed nasal polyposis cases in the 7MM, with approximately 22 million cases, 55% of which were male.
Among emerging treatments for nasal polyposis, Fasenra (Benralizumab) is anticipated to achieve the largest market share by 2034 within the 7MM.
With the expected approval of new therapies during the forecast period from 2024 to 2034, the nasal polyposis therapeutic market is projected to experience significant growth at a substantial compound annual growth rate (CAGR). This market expansion is expected to be driven by the increasing prevalence of nasal polyposis, advancements in diagnostic techniques, a rise in new product launches, and growing research into pharmaceutical treatments.
In March 2024, Optinose announced the U.S. Food and Drug Administration (FDA) has approved XHANCE® (fluticasone propionate) nasal spray for the treatment of chronic rhinosinusitis without nasal polyps in patients 18 years of age and older.
Read detailed insights on Nasal Polyposis market outlook 2034 @ https://www.delveinsight.com/sample-request/nasal-polyposis-market
Nasal Polyposis Overview
Nasal polyposis involves the development of small, benign growths resembling drops within the mucosal lining of the nasal passages, which can cause obstruction. There are two main types of nasal polyps: ethmoidal polyps and antrochoanal polyps. Ethmoidal polyps, which are more common, originate from the ethmoidal sinuses located between the nose and the eyes. Antrochoanal polyps, which are less common, have a different origin. Nasal polyps often result from chronic inflammation due to factors such as infections, allergies, drug reactions, or immune system disorders. Typical symptoms include a runny nose, congestion, and post-nasal drip, although some individuals may have no noticeable symptoms.
Nasal Polyposis Epidemiology Insights:
In 2023, the total number of prevalent Chronic Rhinosinusitis (CRS) cases across the 7MM was approximately 70 million, with significant increases projected by 2034.
In the United States, there were around 8.5 million diagnosed prevalent cases of chronic rhinosinusitis in 2023.
Among the EU4 and the UK, Germany reported the highest number of diagnosed prevalent nasal polyposis cases, with about 6 million cases, followed by the UK with around 4 million cases. Both regions are expected to see substantial changes in these figures by 2034.
Japan reported approximately 2 million diagnosed prevalent cases of nasal polyposis in 2023, ranking second-lowest among the 7MM. This number is anticipated to decrease by 2034.
According to DelveInsight analysis, in Japan in 2023, there were 110,000 diagnosed prevalent cases of nasal polyposis in men and 90,000 cases in women. These gender-specific case numbers are expected to shift by 2034.
Marketed Therapies for Nasal Polyposis
Nucala (Mepolizumab): GlaxoSmithKline
Xhance (Fluticasone Propionate): Optinose US Inc.
Emerging Therapies for Nasal Polyposis
Fasenra (benralizumab): AstraZeneca
Tezepelumab: AstraZeneca/Amgen
Learn How the Nasal Polyposis Market Will Evolve and Grow by 2034 @ https://www.delveinsight.com/report-store/nasal-polyposis-market
Nasal Polyposis Treatment Market
The treatment for nasal polyposis typically involves a combination of pharmacological and surgical methods, tailored to each individual case. Initially, patients are generally managed with medical treatments in a primary care setting before considering surgery. The primary goals of treatment are to eliminate or significantly reduce the size of nasal polyps, alleviate nasal obstruction, enhance sinus drainage, and restore olfaction and taste. Addressing any concurrent rhinitis symptoms may also be necessary. Recurrences are common, especially among patients with asthma, who are twice as likely to experience recurrence compared to those without asthma.
Current treatment options for nasal polyposis include corticosteroids (both intranasal and systemic) and biologics such as Dupixent, Xolair, and Nucala. Corticosteroid implants like Propel and Sinuva are also used to enhance surgical outcomes and manage recurrent nasal polyposis. Additionally, antihistamines, antibiotics, and NSAIDs may be prescribed as needed. If medical treatments are ineffective, surgery may be considered to remove the polyps.
Intranasal glucocorticoids, such as budesonide, fluticasone, and mometasone, can help reduce rhinorrhea, shrink polyp size, and partially or fully restore the sense of smell.
When topical treatments fail to provide relief within 4–6 weeks, a short course of systemic steroids may be necessary. Oral glucocorticoids administered for 2–3 weeks can alleviate symptoms and reduce polyp size, though relief may only last 3–6 months, potentially requiring another course of treatment.
Biologics are also increasingly used for nasal polyposis. Interleukins 4 and 13 are implicated in worsening nasal polyps, and targeting these with dupilumab (Dupixent) has been shown to reduce polyp burden and improve symptoms.
Nasal Polyps Market Dynamics
Pharmaceutical companies are actively addressing challenges and exploring opportunities in nasal polyposis research and development, leading to a surge in potential therapies with innovative treatment approaches. The approval of these new therapies is expected to significantly impact the global nasal polyps treatment market. Contributing factors to market growth include the rising prevalence of nasal polyps, increased global awareness, and more approvals from regulatory agencies.
Despite these advancements, several obstacles could hinder market expansion. These include issues with the misdiagnosis of nasal polyposis, poorly defined tools for assessing disease severity, and a lack of cost-effective treatments. Additionally, a limited clinical pipeline and insufficient awareness about nasal polyps may further constrain market growth.
Leading Players in the Nasal Polyposis Therapeutics Market Include:
Nasal Polyposis Companies working in the market are AstraZeneca, Amgen, Connect Biopharma, GlaxoSmithKline, KeymedBiosciences, Biohaven Pharmaceuticals, and others.
Nasal Polyposis Report Covers the In-depth Assessment of the Emerging Nasal Polyposis Drugs & Key Companies. Download the Nasal Polyposis Market Sample Report to Learn More @ https://www.delveinsight.com/sample-request/nasal-polyposis-market
Table of Contents
1. Key Insights
2. Executive Summary
3. Nasal Polyposis Competitive Intelligence Analysis
4. Nasal Polyposis Market Overview at a Glance
5. Nasal Polyposis Disease Background and Overview
6. Nasal Polyposis Patient Journey
7. Nasal Polyposis Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Nasal Polyposis Treatment Algorithm, Current Treatment, and Medical Practices
9. Nasal Polyposis Unmet Needs
10. Key Endpoints of Nasal Polyposis Treatment
11. Nasal Polyposis Marketed Products
12. Nasal Polyposis Emerging Drugs and Latest Therapeutic Advances
13. Nasal Polyposis Seven Major Market Analysis
14. Attribute Analysis
15. Nasal Polyposis Market Outlook (In US, EU5, and Japan)
16. Nasal Polyposis Access and Reimbursement Overview
17. KOL Views on the Nasal Polyposis Market
18. Nasal Polyposis Market Drivers
19. Nasal Polyposis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Trending Reports by DelveInsight:
Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
